Unbalanced circulating Humanin levels and cardiovascular risk in chronic hemodialysis patients: a pilot, prospective study.

Bolignano D, Greco M, Presta P, Duni A, Zicarelli M, Mercuri S, Pappas E, Lakkas L, Musolino M, Naka KK, Pugliese S, Misiti R and 4 more

Show all authors

Foti DP, Andreucci M, Coppolino G, Dounousi E

Journal of nephrology5 Aug 2024Cited by 3 (Europe PMC)

PMID39102184PMCIDPMC11519124DOI10.1007/s40620-024-02032-4PepBankPUB-39102184

Download PDF PubMedAsk about this study

Jump to 6 results

Summary

BackgroundMortality and cardiovascular (CV) risk prediction in individuals with end-stage kidney disease (ESKD) on chronic hemodialysis (HD) remains challenging due to the multitude of implicated factors. In a multicenter ESKD-HD cohort, we tested the prognostic yield of the assessment of circulating Humanin, a small mitochondrial-derived peptide involved in CV protection, on CV events and mortality.MethodsWe conducted a prospective, observational, pilot study on 94 prevalent HD patients. The prognostic capacity of circulating Humanin levels was tested on a primary composite (all-cause mortality + non-fatal CV events) and a secondary exploratory endpoint (all-cause mortality alone).ResultsBaseline Humanin level was comparable in patients reaching the primary or secondary endpoint as compared to others (p = 0.69 and 0.76, respectively). Unadjusted followed by multivariable Cox regression analyses adjusted for age, left ventricular mass index (LVMi), E/e', pulse pressure and diabetes mellitus indicated a non-linear relationship between Humanin levels and the composite outcome with the highest Hazard Ratio (HR) associated with very low (< 450.7 pg/mL; HR ranging from 4.25 to 2.49) and very high (> 759.5 pg/mL; HR ranging from 5.84 to 4.50) Humanin values. Restricted cubic splines fitting univariate and multivariate Cox regression analyses visually confirmed a curvilinear trend with an increasing risk observed for lower and higher Humanin values around the median, respectively. A similar, u-shaped association was also evidenced with the secondary endpoint.ConclusionsAltered Humanin levels may impart prognostic information in ESKD-HD patients at risk of death or CV events. Future investigations are needed to confirm whether Humanin measurement could improve CV and mortality risk prediction beyond traditional risk models.

CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study6

No result from this study comes from a test of the peptide.

Natural levels measured6

These results measure the body's own peptide. Nobody was given the peptide. They are not evidence about taking it. They are left out of key results, evidence counts and charts.

01HumanEndogenous levelObservational studyOther
In hemodialysis patients, baseline circulating humanin was comparable in patients who reached the primary composite endpoint and in others.
In plain wordsIn people on hemodialysis, the body's own humanin level at the start was similar with or without a later death or heart event.
Peptide
Humanin
Outcome
No significant changeBaseline humanin versus primary composite endpoint
Study
n = 94
Comparator
Patients not reaching the endpoint
Analysis
Primary
Outcome group
Cardiovascular events · Cardiovascular
Measurements
p value
0.69
primary endpoint
Source sentences
Summary
Baseline Humanin level was comparable in patients reaching the primary or secondary endpoint as compared to others (p = 0.69 and 0.76, respectively).
1 context sentence(design, population, supporting numbers)
Summary · context
We conducted a prospective, observational, pilot study on 94 prevalent HD patients.
This result measures the body's own Humanin. Nobody was given the peptide. It is not evidence about taking it.
Show in the study text Report a problemFND-3910218401
02HumanEndogenous levelObservational studyOther
In hemodialysis patients, Cox regression indicated a non-linear, curvilinear relationship between circulating humanin and the composite outcome.
In plain wordsIn people on hemodialysis, both lower and higher levels of the body's own humanin were linked to more death or heart events.
Peptide
Humanin
Outcome
MixedNon-linear relationship of humanin with composite outcome
Study
n = 94
Analysis
Primary
Outcome group
Cardiovascular events · Cardiovascular
Source sentences
Summary
indicated a non-linear relationship between Humanin levels and the composite outcome
2 context sentences(design, population, supporting numbers)
Summary · context
Restricted cubic splines fitting univariate and multivariate Cox regression analyses visually confirmed a curvilinear trend with an increasing risk observed for lower and higher Humanin values around the median, respectively.
Summary · context
We conducted a prospective, observational, pilot study on 94 prevalent HD patients.
This result measures the body's own Humanin. Nobody was given the peptide. It is not evidence about taking it.
Show in the study text Report a problemFND-3910218403
03HumanEndogenous levelObservational studyOther
In hemodialysis patients, very low circulating humanin was associated with a higher hazard ratio for the composite outcome.
In plain wordsIn people on hemodialysis, very low levels of the body's own humanin were linked to a higher risk of death or heart events.
Peptide
Humanin
Outcome
IncreaseHazard ratio for very low humanin
Study
n = 94
Analysis
Primary
Outcome group
Cardiovascular events · Cardiovascular
Measurements
humanin threshold
< 450.7 pg/mL
very low humanin
Source sentences
Summary
highest Hazard Ratio (HR) associated with very low (< 450.7 pg/mL; HR ranging from 4.25 to 2.49)
1 context sentence(design, population, supporting numbers)
Summary · context
We conducted a prospective, observational, pilot study on 94 prevalent HD patients.
This result measures the body's own Humanin. Nobody was given the peptide. It is not evidence about taking it.
Show in the study text Report a problemFND-3910218404
04HumanEndogenous levelObservational studyOther
In hemodialysis patients, very high circulating humanin was associated with a higher hazard ratio for the composite outcome.
In plain wordsIn people on hemodialysis, very high levels of the body's own humanin were linked to a higher risk of death or heart events.
Peptide
Humanin
Outcome
IncreaseHazard ratio for very high humanin
Study
n = 94
Analysis
Primary
Outcome group
Cardiovascular events · Cardiovascular
Measurements
humanin threshold
> 759.5 pg/mL
very high humanin
Source sentences
Summary
very high (> 759.5 pg/mL; HR ranging from 5.84 to 4.50) Humanin values
1 context sentence(design, population, supporting numbers)
Summary · context
We conducted a prospective, observational, pilot study on 94 prevalent HD patients.
This result measures the body's own Humanin. Nobody was given the peptide. It is not evidence about taking it.
Show in the study text Report a problemFND-3910218405
05HumanEndogenous levelObservational studyOther
In hemodialysis patients, baseline circulating humanin was comparable in patients who reached the secondary endpoint of all-cause mortality and in others.
In plain wordsIn people on hemodialysis, the body's own humanin level at the start was similar in those who died and those who did not.
Peptide
Humanin
Outcome
No significant changeBaseline humanin versus all-cause mortality
Study
n = 94
Comparator
Patients not reaching the endpoint
Analysis
Secondary
Outcome group
Cardiovascular events · Cardiovascular
Measurements
p value
0.76
secondary endpoint
Source sentences
Summary
Baseline Humanin level was comparable in patients reaching the primary or secondary endpoint as compared to others (p = 0.69 and 0.76, respectively).
1 context sentence(design, population, supporting numbers)
Summary · context
We conducted a prospective, observational, pilot study on 94 prevalent HD patients.
This result measures the body's own Humanin. Nobody was given the peptide. It is not evidence about taking it.
Show in the study text Report a problemFND-3910218402
06HumanEndogenous levelObservational studyOther
In hemodialysis patients, a similar u-shaped association was found between circulating humanin and all-cause mortality.
In plain wordsIn people on hemodialysis, both low and high levels of the body's own humanin were linked to more deaths.
Peptide
Humanin
Outcome
MixedHumanin association with all-cause mortality
Study
n = 94
Analysis
Secondary
Outcome group
Cardiovascular events · Cardiovascular
Source sentences
Summary
A similar, u-shaped association was also evidenced with the secondary endpoint.
1 context sentence(design, population, supporting numbers)
Summary · context
We conducted a prospective, observational, pilot study on 94 prevalent HD patients.
This result measures the body's own Humanin. Nobody was given the peptide. It is not evidence about taking it.
Show in the study text Report a problemFND-3910218406

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
13 Oct 2026, 21:44 UTC
Study results updated
Version 1
13 Oct 2026, 16:31 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.